Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05454956 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT05454956: Completed Phase 2 study, sponsored by Tarsus Pharmaceuticals.
NCT05454956 is a Phase 2 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05454956, a Phase 2 study, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
Primary Outcome
Number of participants with TEAEs related (definitely or potentially) to treatment summarized by MedDRA preferred term.
Interventions
- DRUG TP-03
- DRUG TP-03 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 2 |
What the finished NCT05454956 record still lists
NCT05454956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which TP-03 is the first listed.
NCT05454956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05454956 about?
NCT05454956 is a clinical study titled "Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD". The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
What is the current status of trial NCT05454956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2022-08-03. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT05454956?
The interventions under investigation include: TP-03 (DRUG), TP-03 Vehicle (DRUG).
Who is sponsoring clinical trial NCT05454956?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05454956's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI